Measuring the cerebral blood flow and cerebrovascular reactivity is vital in the preoperative assessment of moyamoya patients. We propose a combination of continuous multiband BOLD-MRI and multidelay ASL-MRI with acetazolamide as a comprehensive multi-modal alternative for the current commonly used PET-CT method. Eight female patients (age 8-41) were scanned at 3T with a ±30 min scan protocol, which is also suitable for patients scanned under general anesthesia. The obtained reactivity maps of the two sequences showed good agreement for severity and location of hemodynamic impairment. This accessible MRI method is directly suitable for routine clinical evaluation of moyamoya patients.
1. Kronenburg
A, Braun KPJ, Van Der Zwan A, Klijn CJM. Recent advances in moyamoya disease: Pathophysiology and treatment. Curr
Neurol Neurosci Rep. 2014;14(1):1-9. doi:10.1007/s11910-013-0423-7.
2. Fierstra J,
van Niftrik C, Warnock G, et al. Staging Hemodynamic
Failure With Blood Oxygen-Level-Dependent Functional Magnetic Resonance Imaging
Cerebrovascular Reactivity: A Comparison Versus Gold Standard
((15)O-)H2O-Positron Emission Tomography. Stroke. 2018;49(3):621-629. doi:10.1161/STROKEAHA.117.020010.
3. Fan AP,
Khalighi MM, Guo J, et al. Identifying
Hypoperfusion in Moyamoya Disease With Arterial Spin Labeling and an [ 15
O]-Water Positron Emission Tomography/Magnetic Resonance Imaging Normative
Database. Stroke. 2019;50(2):373-380. doi:10.1161/STROKEAHA.118.023426.
4. Juttukonda MR,
Donahue MJ. Neuroimaging of vascular reserve in patients with cerebrovascular
diseases. Neuroimage. 2019;187(August 2017):192-208.
doi:10.1016/j.neuroimage.2017.10.015.
5. Donahue MJ,
Achten E, Cogswell PM, et al. Consensus statement on current and emerging methods
for the diagnosis and evaluation of cerebrovascular disease. J Cereb Blood
Flow Metab. 2018;38(9):1391-1417. doi:10.1177/0271678X17721830.
6. Siero JCW,
Hartkamp NS, Donahue MJ, et al. Neuronal activation induced BOLD and CBF
responses upon acetazolamide administration in patients with steno-occlusive
artery disease. NeuroImage Clin. 2015;105:276-285.
doi:doi:10.1016/j.neuroimage.2014.09.033.
7. Fan AP, Guo J,
Khalighi MM, et al. Long-Delay Arterial Spin Labeling Provides More Accurate
Cerebral Blood Flow Measurements in Moyamoya Patients: A Simultaneous Positron
Emission Tomography/MRI Study. Stroke. 2017;48(9):2441-2449.
doi:10.1161/STROKEAHA.117.017773.
8. Faraco, Carlos
C Strother, Megan Donahue M. Dual echo vessel‐encoded ASL for simultaneous BOLD
and CBF reactivity assessment in patients with ischemic cerebrovascular
disease.pdf. 2014. doi:https://doi.org/10.1002/mrm.25268.
9. Lee M,
Zaharchuk G, Guzman R, Achrol A, Bell-Stephens T, Steinberg GK. Quantitative
hemodynamic studies in moyamoya disease: a review. Neurosurg Focus.
2009;26(4):E5. doi:10.3171/2009.1.FOCUS08300.
10. Hauser T-K,
Seeger A, Bender B, et al. Hypercapnic BOLD MRI
compared to H2(15)O PET/CT for the hemodynamic evaluation of patients with
Moyamoya Disease. NeuroImage Clin. 2019;22:101713.
doi:10.1016/j.nicl.2019.101713.
11. Pellaton A,
Bijlenga P, Bouchez L, et al. CO 2 BOLD assessment of moyamoya syndrome:
Validation with single photon emission computed tomography and positron
emission tomography imaging . World J Radiol. 2016;8(11):887.
doi:10.4329/wjr.v8.i11.887.
12. Goetti R,
Warnock G, Kuhn FP, et al. Quantitative cerebral perfusion imaging in children
and young adults with Moyamoya disease: Comparison of arterial
spin-labeling-MRI and H2[15O]-PET. Am J Neuroradiol.
2014;35(5):1022-1028. doi:10.3174/ajnr.A3799.
13. Sobczyk O,
Battisti-Charbonney A, Fierstra J, et al. A conceptual model for CO2-induced
redistribution of cerebral blood flow with experimental confirmation using BOLD
MRI. Neuroimage. 2014;92:56-68. doi:10.1016/j.neuroimage.2014.01.051.
14. Bhogal AA,
Philippens MEP, Siero JCW, et al. Examining the regional and cerebral
depth-dependent BOLD cerebrovascular reactivity response at 7T. Neuroimage.
2015;114:239-248. doi:10.1016/j.neuroimage.2015.04.014.
Table 1: Baseline characteristics and scan properties.
Abbreviations: MMD: moyamoya disease; MMS: moyamoya syndrome; BOLD: blood oxygen level dependent; ASL: arterial spin labeling.
Figure 1: Outline of scan protocol
Preliminary and pragmatic clinical protocol for hemodynamic evaluation. Abbreviations: md-ASL: multidelay arterial spin labeling MRI; BOLD: blood oxygen level dependent MRI. ACZ: acetazolamide. X-axis: time in minutes, with different scan sequences. Y-axis: effect of ACZ on CBF.
Figure
2: example of 2 patients
Patient 1 is
a 14 y/o girl with unilateral moyamoya for which she received a direct bypass on the left side. She
had new neurological deficits and the scans show a severe perfusion defect on the left,
with still some reactivity. Patient 2 is a 10 y/o girl who received a bilateral
direct bypass. 1 year later the scans show improved CVR on both ASL and PET.
Figure
3: Example of a dataset of a 41 y/o preoperative
patient with unilateral MMV. A.) shows standard clinical scans, MRA and T2
Flair. The green arrow shows
stenosis and formation of collaterals. The BOLD (B) shows the CBF change after
ACZ injection, with impaired CVR left parieto-frontally, also seen on the ASL
(C). There is steal visible (blue arrow)
and arterial transit artifacts (red
arrow). Using the BOLD it is possible to show these apparent high CBF
regions are indeed artefacts and actually show regions with low cerebrovascular reactivity.
Figure
4: effect of stimulus on different vessels. A is
the (schematic) resting point of healthy vessels and B the resting point of impaired
vessels. The y-axis shows the dilatory capacity, the x-axes the pCO2.
Acetazolamide (ACZ) raises the pCO2. With the same stimulus (red line) different responses are
elicited from both vessels (green line).
Although the impaired vessels may react slightly, the pressure difference after
dilation will lead to redistribution of blood, causing vascular steal in the impaired region (as shown on the right).